|
|
|
|
 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- [2002]
(click to view the full text)
|
September 18, 2002
Æterna Details Contractual Arrangements Between Shareholders with Respect to the S&P/TSX Composite Index |
September 13, 2002
Appointment to Æterna Management |
October 29, 2002
FDA Grants Orphan-Drug Status to Æterna’s Neovastat® for Kidney Cancer |
October 22, 2002
Æterna Reports Third Quarter Results |
October 8, 2002
Æterna: Additional Collaboration for Phase III Lung Cancer Trial |
October 2, 2002
Æterna signs a new agreement for marketing Neovastat ™ in Australia, Canada and Mexico - Exclusive rights granted to Mayne Pharma, an Australian multinational |
May 21, 2002
Æterna: Neovastat's Favorable Safety Profile in Phase III Trials Confirmed by Independent Safety Monitoring Boards |
May 1, 2002
Æterna’s subsidiary Atrium makes a second acquisition in France |
June 12, 2002
Æterna Holds Annual Shareholder Meeting: Results of Phase III Trial in Kidney Cancer in 2003 - First Marketing Opportunity for Neovastat in 2004 |
July 18, 2002
Æterna Reports Second Quarter Results |
February 19, 2002
Æterna reports financial results for 2001 |
December 30, 2002
Æterna acquires German biopharmaceutical Zentaris from Degussa |
December 18, 2002
Dr. Éric Dupont, Chairman of the Board and Chief Executive Officer of Æterna Laboratories Inc. Makes a Personal Donation of CDN $1 Million to Five Cancer Charities |
April 16, 2002
Æterna Laboratories reports first quarter results |
April 10, 2002
New appointments to Æterna management and Board of Directors |
April 9, 2002
Initial investment of $57 million in Æterna by SGF Santé, Solidarity Fund QFL and Acqua Wellington |
 |
 |
|
|
|
